Corton Capital Inc. Makes New Investment in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Corton Capital Inc. purchased a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 3,217 shares of the medical instruments supplier's stock, valued at approximately $296,000.

Several other hedge funds have also made changes to their positions in the stock. Copeland Capital Management LLC grew its holdings in shares of LeMaitre Vascular by 0.7% in the 4th quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier's stock worth $107,990,000 after acquiring an additional 8,623 shares during the last quarter. Congress Asset Management Co. increased its stake in shares of LeMaitre Vascular by 1.8% in the fourth quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier's stock worth $66,555,000 after purchasing an additional 13,009 shares during the period. Geode Capital Management LLC increased its stake in shares of LeMaitre Vascular by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier's stock worth $50,711,000 after purchasing an additional 7,737 shares during the period. Northern Trust Corp increased its stake in LeMaitre Vascular by 5.1% during the fourth quarter. Northern Trust Corp now owns 327,815 shares of the medical instruments supplier's stock valued at $30,205,000 after acquiring an additional 15,843 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of LeMaitre Vascular by 0.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 284,779 shares of the medical instruments supplier's stock valued at $26,240,000 after purchasing an additional 1,680 shares during the period. Institutional investors own 84.64% of the company's stock.

Insider Transactions at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,009 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares in the company, valued at approximately $456,915.68. This represents a 26.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 10.79% of the stock is owned by company insiders.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT traded up $2.80 during mid-day trading on Monday, hitting $83.06. The stock had a trading volume of 62,879 shares, compared to its average volume of 162,921. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of 45.35, a PEG ratio of 2.22 and a beta of 0.86. The company's 50 day simple moving average is $84.15 and its 200 day simple moving average is $93.14.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. During the same quarter last year, the business earned $0.44 earnings per share. The company's revenue was up 12.0% on a year-over-year basis. As a group, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th will be issued a dividend of $0.20 per share. The ex-dividend date is Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.96%. LeMaitre Vascular's dividend payout ratio (DPR) is presently 40.40%.

Analyst Ratings Changes

LMAT has been the topic of several recent analyst reports. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 target price on the stock. Oppenheimer downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Finally, Lake Street Capital upped their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $98.14.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.